NCT05027061 is a clinical trial in Non-Valvular Atrial Fibrillation (NVAF), sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT05027061?

NCT05027061 is sponsored by Bristol-Myers Squibb.

What condition does NCT05027061 study?

NCT05027061 studies Non-Valvular Atrial Fibrillation (NVAF).

Is NCT05027061 still recruiting?

NCT05027061 is currently completed. Last updated 17 March 2022.

Last reviewed 2022-03-17 · How we verify

NCT05027061

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan

Completed Last updated 17 March 2022

What this trial tests

trial in Non-Valvular Atrial Fibrillation (NVAF) in 11,776 participants. Completed in 4 December 2021.

Timeline

2 April 2021

Primary endpoint
4 December 2021

4 December 2021

Quick facts

Lead sponsor	Bristol-Myers Squibb
Status	Completed
Study type	OBSERVATIONAL
Enrollment	11,776
Start date	2 April 2021
Primary completion	4 December 2021
Estimated completion	4 December 2021
Sites	1 location across Japan

Conditions studied

Non-Valvular Atrial Fibrillation (NVAF) — all drugs for Non-Valvular Atrial Fibrillation (NVAF) →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

20 and older, any sex, with Non-Valvular Atrial Fibrillation (NVAF). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Non-Valvular Atrial Fibrillation (NVAF)

Currently open trials in the same condition.

NCT05232643 — A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly P · recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05027061 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 17 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05027061.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing